• LAST PRICE
    9.3900
  • TODAY'S CHANGE (%)
    Trending Down-0.3000 (-3.0960%)
  • Bid / Lots
    9.2500/ 10
  • Ask / Lots
    9.3900/ 5
  • Open / Previous Close
    9.5900 / 9.6900
  • Day Range
    Low 9.2300
    High 9.7800
  • 52 Week Range
    Low 2.1800
    High 13.6800
  • Volume
    268,746
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 9.69
TimeVolumeLRMR
09:32 ET29119.59
09:38 ET5269.6587
09:39 ET4109.65
09:41 ET2609.7759
09:43 ET1009.69
09:45 ET11409.62
09:52 ET27009.56
09:54 ET47059.685
09:56 ET18009.61
09:57 ET10009.5783
10:01 ET1009.65
10:03 ET29699.59
10:06 ET24549.55
10:08 ET14509.6
10:14 ET10009.6206
10:15 ET1009.639
10:17 ET2029.66
10:19 ET14469.67
10:21 ET1009.69
10:26 ET19529.65
10:30 ET11009.65
10:33 ET7009.6
10:35 ET29009.605
10:37 ET22009.5601
10:39 ET61109.54
10:42 ET9399.56
10:44 ET2509.58
10:46 ET7209.58
10:48 ET1009.62
10:53 ET4999.659
10:55 ET1009.659
11:00 ET21669.64
11:04 ET2009.63
11:18 ET1009.58
11:20 ET1009.57
11:27 ET4009.615
11:29 ET2009.65
11:31 ET4609.65
11:33 ET1009.66
11:36 ET2009.64
11:40 ET5899.63
11:45 ET3009.57
11:54 ET2009.565
11:56 ET5819.57
11:58 ET56009.55
12:00 ET6139.535
12:03 ET9009.55
12:07 ET1409.58
12:12 ET1009.57
12:16 ET5009.59
12:20 ET2719.6
12:23 ET9509.57
12:30 ET5009.52
12:32 ET5009.52
12:38 ET51009.52
12:39 ET2009.53
12:41 ET2009.53
12:43 ET1529.5063
12:45 ET2009.51
12:48 ET59939.49
12:50 ET68579.53
12:52 ET5009.53
12:54 ET1609.55
12:56 ET45009.55
12:57 ET1009.5101
01:01 ET10009.58
01:03 ET21639.61
01:08 ET1009.6
01:10 ET11509.615
01:12 ET1009.62
01:15 ET3339.63
01:19 ET1009.635
01:21 ET1729.635
01:24 ET7009.58
01:26 ET2009.59
01:28 ET4009.58
01:32 ET2389.59
01:37 ET7009.57
01:39 ET1009.55
01:42 ET3009.51
01:44 ET2009.48
01:46 ET4009.48
01:51 ET26529.48
01:55 ET11109.42
01:57 ET7009.36
02:00 ET50209.3201
02:02 ET27789.3101
02:06 ET6609.325
02:08 ET2009.34
02:09 ET4079.31
02:11 ET5009.31
02:13 ET48469.2856
02:15 ET3009.2703
02:18 ET27559.25
02:20 ET15699.25
02:24 ET1009.24
02:26 ET24989.2407
02:27 ET8009.265
02:29 ET13009.3
02:31 ET5009.29
02:36 ET2269.27
02:38 ET1009.25
02:40 ET2009.24
02:45 ET1009.23
02:49 ET14009.2826
02:51 ET1089.28
02:54 ET10099.31
02:56 ET15009.31
02:58 ET2009.3
03:00 ET10509.3029
03:03 ET35009.3
03:05 ET1009.3
03:07 ET9509.305
03:12 ET1009.3
03:16 ET16059.31
03:18 ET10509.31
03:20 ET11009.3
03:23 ET32009.36
03:27 ET22639.41
03:30 ET4009.419
03:32 ET2009.42
03:36 ET2009.435
03:38 ET1009.43
03:39 ET6009.435
03:41 ET3009.43
03:43 ET26759.43
03:45 ET10559.42
03:48 ET5009.4
03:50 ET3009.4
03:52 ET36009.42
03:54 ET18009.42
03:56 ET17499.39
03:57 ET38849.395
03:59 ET313699.39
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLRMR
Larimar Therapeutics Inc
599.1M
-9.7x
---
United StatesLYEL
Lyell Immunopharma Inc
601.7M
-2.6x
---
United StatesOCS
Oculis Holding AG
550.3M
-6.4x
---
United StatesANNX
Annexon Inc
581.6M
-3.8x
---
United StatesGHRS
GH Research PLC
623.8M
-17.5x
---
United StatesMLYS
Mineralys Therapeutics Inc
624.6M
-5.8x
---
As of 2024-06-15

Company Information

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Contact Information

Headquarters
THREE BALA PLAZA EAST. SUITE 506BALA CYNWYD, PA, United States 19004
Phone
617-622-4003
Fax
302-655-5049

Executives

Independent Chairman of the Board
Joseph Truitt
President, Chief Executive Officer, Director
Carole Ben-Maimon
Chief Financial Officer, Secretary
Michael Celano
Chief Medical Officer
Russell Clayton
Chief Development Officer
Gopi Shankar

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$599.1M
Revenue (TTM)
$0.00
Shares Outstanding
63.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.04
EPS
$-0.97
Book Value
$1.86
P/E Ratio
-9.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.